Current Issue:
homepage - Therapeutics Pharmacology and Clinical Toxicology
print subscribe
newsletter subscribe

The management of hematological side effects in chronic hepatitis C treatment

Ionescu R.A., Daha Ioana Cristina, Onogea C., Nitescu Doina, Tanasescu C.
Abstract: The side effects of chronic hepatitis C treatment can have a significant impact on the desired treatment outcome defined as SVR (sustained virological response - absence of detectable RNA of the hepatitis C virus in blood serum for at least six months after treatment completion). The aim of this study was to retrospectively assess the effect of different management approaches for hematological side effects in a group of patients treated for chronic hepatitis C with peg-interferon and ribavirin, at the National Institute for Infectious Diseases `Prof. Dr. Matei Bals`, from November 2009 to December 2010. The SVR for the studied group was 65%, with a lack of statistical correlation between age group, gender, baseline viremia and SVR rate. The study results showed that anemia management by ribavirin dose reduction and erythropoietin administration had no effect on the sustained virological response rate, whereas for patients with neutropenia, maintaining constant peg-interferon doses displayed a significant effect on the sustained virological response rate. There was no correlation between developing hematological side effects and the SVR rate.

Keywords: hepatitis C, interferon, ribavirin, anemia, neutropenia


Arhive Category